Publications by authors named "David Demanse"

Claim this Profile
N
New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials.
Anna Passera, Elisa Muscianisi, David Demanse, Ginette A Okoye, Gregor B E Jemec

J Eur Acad Dermatol Venereol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.
Benjamin J Solomon, Daniel S W Tan, Gilberto de Castro, Manuel Cobo, Marina Chiara Garassino, David Demanse

Cancer Res Commun· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time-to-event endpoints.
Matthias Kormaksson, Markus Reiner Lange, David Demanse, Susanne Strohmaier, Jiawei Duan

Stat Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, Balazs Halmos, Byoung Chul Cho, David Demanse

Lung Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Jordi Rodón, David Demanse, Hope S Rugo, Howard A Burris, Rafael Simó

Breast Cancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Albiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, Myung-Ju Ahn, Pamela Munster, David Demanse

Target Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of digital measures and self-reported fatigue: a remote observational study in healthy participants and participants with chronic inflammatory rheumatic disease.
Chaitra Rao, Elena Di Lascio, David Demanse, Nell Marshall, Monika Sopala

Front Digit Health· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unsupervised machine-learning algorithms for the identification of clinical phenotypes in the osteoarthritis initiative database.
David Demanse, Franziska Saxer, Patrick Lustenberger, László B Tankó, Philipp Nikolaus

Semin Arthritis Rheum· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401).
Mélanie Wilbaux, Shu Yang, Astrid Jullion, David Demanse, Diana Graus Porta

Clin Pharmacol Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment.
Mélanie Wilbaux, David Demanse, Yi Gu, Astrid Jullion, Andrea Myers

CPT Pharmacometrics Syst Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Dejan Juric, Filip Janku, Jordi Rodón, Howard A Burris, Ingrid A Mayer, David Demanse

JAMA Oncol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Stephen J Luen, Rebecca Asher, Chee Khoon Lee, Peter Savas, Roswitha Kammler, David Demanse

JAMA Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, Howard Burris, Angel Guerrero-Zotano, David Demanse

Cancer Chemother Pharmacol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Dejan Juric, Jordi Rodon, Josep Tabernero, Filip Janku, Howard A Burris, David Demanse

J Clin Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Philippe L Bedard, Josep Tabernero, Filip Janku, Zev A Wainberg, Luis Paz-Ares, David Demanse

Clin Cancer Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Johanna C Bendell, Jordi Rodon, Howard A Burris, Maja de Jonge, Jaap Verweij, David Demanse

J Clin Oncol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
Morgan Rouprêt, Vincent Hupertan, Eva Comperat, Sarah J Drouin, Véronique Phé, David Demanse

BJU Int· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis